Considerable progress is being made in the transfer of genetic material to hematopoietic stem cells. In this chapter we describe how gene transfer is being used to: mark marrow and peripheral blood progenitor cells prior to autologous transplantation, to track their fate on reinfusion and to detect contaminating tumorigenic cells; modulate immunocyte function - important in immunologic disorders and perhaps in cancer therapy; generate tumor vaccines from tumor cells isolated from marrow; correct single gene defects - the 'classical' concept of gene therapy; and finally to modify the drug sensitivity of progenitor cells enabling them to resist the suppressive effects of cytotoxic drugs during cancer therapy and perhaps providing a mechanism for in vivo selection of gene modified cells.
|Original language||English (US)|
|Number of pages||25|
|Journal||British Medical Bulletin|
|State||Published - Jan 1 1995|
ASJC Scopus subject areas